Frank is an accomplished Pharma and Biotech senior executive with over 20 years experience. Between 2002 and 2009, he was with Wyeth (Collegeville PA, USA), where he served as Executive Vice President and Head of Discovery Research Worldwide. This involved managing more than 1500 scientists across seven sites globally and delivering multiple products in diverse areas to IND and late stage clinical trials. Prior to joining Wyeth, Frank was at GlaxoSmithKline (UK) where he was Senior Vice President and Head of the Neurology Centre of Excellence for Drug Discovery. From 1997 to 2000, he was Vice President and Head of Neuroscience Research at SmithKline Beecham (UK). Before moving to industry, Frank had a distinguished academic career, during which he authored over 200 scientific publications. He was the Research Dean at the United Medical and Dental Schools of Guys and St. Thomas’ Hospitals (London, UK), and also the Sir William Dunn Professor of Experimental Pathology and previously worked at the Institute of Neurology Queen Square, London. He has honorary degrees from the University of Perugia, University of Bologna, University of Strathclyde and University of Dundee. He is a Fellow of King’s College London, a Fellow of the Academy of Medical Sciences London and a Corresponding Fellow of the Royal Society of Edinburgh.
Lynn is a distinguished Neuroscientist and Pharmacologist with extensive expertise in Translational Medicine. She was formerly AVP of Translational Medicine at Wyeth in Collegeville, PA and co-led the Translational Medicine Research Collaboration in Scotland (TMRC). She was head of Product Development at Neuronyx in Malvern, PA working on mesenchymal stem cell products with the late Hubert Schoemaker, co-founder of Cenotcor, one of the first biotech companies to produce therapeutic monoclonal antibodies. Before joining industry, Lynn has over 15 years of academic research experience as a NIH-funded principal investigator with faculty appointments in Neurology at University of Pennsylvania, University of Michigan and Johns Hopkins University working on Schwann cell biology and Neurofibromatosis. Lynn received her PhD in Pharmacology and Toxicology with a focus on Neuropharmacology, from the University of Maryland, Baltimore.
Steve has spent the last 20 years in Pharma and Biotech both managing research organizations and research projects. Prior to joining Ossianix in 2012, he was site head at the Translational Medicine Research Collaboration laboratory in Dundee, Scotland. Prior to that, he managed GI biology research at Glaxo Smith Kline UK in the Neurology/GI CEDD and at Smith Kline Beecham Neuroscience he was a team leader in Neurodegeneration. Steve received his Ph.D. in Biochemistry from the Institute of Neurology, University of London and worked at Guys & St Thomas’s Medical School, as Principal Medical Laboratory Scientist in Experimental Pathology before joining industry.